nick

Opinions are my own and do not represent my employer in any way.

[nick @NickAndBiotech]

@jianguangchen how was glacier?

[nick @NickAndBiotech]

@3Lz3Lo3A @RahulBanerjeeMD @PlasmaCellPete When will JNJ run a bsAb versus ex vivo CAR-T study?

[nick @NickAndBiotech]

@Biohazard3737 Would you consider an oral + Subcu/IV IL-23 combo after you lose your response on an oral (whether it’s obe or Ico assuming it works in IBD)?

[nick @NickAndBiotech]

@STL_Biotech Can I add RLYP/ZSPH to the list 😃

[nick @NickAndBiotech]

@MaverickNY @BiotechStrategy Is that rule still applicable today?

[nick @NickAndBiotech]

@plainyogurt21 🤝

[nick @NickAndBiotech]

@andrewpannu Sleuth

[nick @NickAndBiotech]

@CapitalShipyard

[nick @NickAndBiotech]

@CamillusMiura Any read through from phase 2 luti data?

[Dr.Monica Avila @MAvilaMD]

RUBY @GSK updated 4yr survival data with additional 30mo FU showing median PFS and OS not yet reached at #SGOAAM26. Only 4 more progression events with 73% response at 48mo and 66% reduction in hazard ☣️. WILD. First shot, best chance with immunotherapy.

[nick @NickAndBiotech]

@Sanctuary_Bio ACAD

[nick @NickAndBiotech]

@TheBiotechBear 😂😂

[nick @NickAndBiotech]

@bioinvestor24 @semodough rationale? assuming base case is being in line with opdualag

[nick @NickAndBiotech]

@STL_Biotech dose escalation? lol

[nick @NickAndBiotech]

@fakepharmabro i’m assuming you will still need to run chronic tox studies once you’re in the clinic?

[Luciano J Costa @End_myeloma]

MajesTEC-3 ASH LBA

Best result ever in a RRMM randomized trial. It will transform how we approach myeloma. Congratulations to authors and @JNJNews

https://t.co/UhNOesmjXd

[nick @NickAndBiotech]

@MartinShkreli wasn’t cubist fully impaired within two years? Lmao

[PRV Watch @PRVWatch]

🚨Just announced, the FDA has awarded six additional Commissioner’s National Priority Vouchers:
- Zongertinib (Boehringer Ingelheim) for HER2 lung cancer
- Bedaquiline ( $JNJ Johnson & Johnson) for drug-resistant TB in young children
- Dostarlimab ( $GSK GSK ) for rectal cancer
- Casgevy ( $VRTX Vertex) for sickle cell disease
- Orforglipron ( $LLY Eli Lilly) for obesity and related health conditions
- Wegovy ( $NVO Novo Nordisk) for obesity and related health conditions

[nick @NickAndBiotech]

@BiotechSho99376 First to market has advantages - but in a large enough market, even with minor differentiation on clinical profile or dosing intervals, can be a meaningful opportunity. Also from BP perspective preclin assets from China are cheaper than ones in the US and can move into FIG sooner

[nick @NickAndBiotech]

@Se19edy 🔥🔥